1-6 of 6
Stephen Schey, MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Quality of Life Data from a Prospective Randomised Trial of Newly Diagnosed Myeloma Patients with Renal Failure: Optimal Trial

Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Gulnaz Iqbal, PhD, Mark T Drayson, MB ChB, PhD FRCPath, Richard Brouwer, BSc, Sherin Varghese, MSc, BA, Stephen Schey, MBBS, Jindriska Lindsay, FRCPath, Janet Dunn, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 5–6.
https://doi.org/10.1182/blood-2020-140937
Published: 2020
Journal Articles

Optimal - a Study of Bortezomib, Bendamustine and Dexamethasone (BBD) Vs Thalidomide, Bendamustine and Dexamethasone (BTD) in Patients with Renal Failure Defined As an Egfr below 30 Mls/Min

Karthik Ramasamy, MBBS MRCP FRCPath PhD, Mark T Drayson, MB ChB, PhD FRCPath, Gulnaz Iqbal, PhD, Victoria Stalker, BSc, MA, Salma Akhtar, BSc, MSc, Janet Dunn, PhD, Stephen Schey, MBBS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3135.
https://doi.org/10.1182/blood-2019-128157
Published: 2019
Journal Articles

A Seven Gene Signature to Distinguish Bortezomib- and Lenalidomide-Responsive Myeloma: Rnaseq from the Padimac Study

Michael Chapman, PhD MRCP, FRCPath, Jonathan Sive, John Ambrose, Claire Roddie, PhD MD, Nicholas Counsell, Paul Smith, Nivette Braganza, Toyin Adedayo, Rakesh Popat, MD PhD, James D Cavenagh, Matthew J. Streetly, BMBS, PhD MRCP, FRCPath, Roger G. Owen, MD, Stephen Schey, MBBS, Mickey Koh, MD PhD, Josephine Crowe, Michael F. Quinn, FRCPath, MB, MD MRCP, Shirley D'Sa, MD FRCP, FRCPath, Andres E. Virchis, FRCP, FRCPath, Gordon Cook, PhD, Charles R Crawley, Guy Pratt, MD FRCP, FRCPath, Mark Cook, MBChB,PhD, Laura Clifton-Hadley, PhDBSc, Javier Herrero, PhD, Kwee Yong, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 267.
https://doi.org/10.1182/blood.V130.Suppl_1.267.267
Published: 2017
Journal Articles

Outcomes of Stratification to ASCT or Not Based on Depth of Response: Results of a Phase 2 Trial Assessing the Impact of Minimal Residual Disease (MRD) in Multiple Myeloma Patients with Deferred ASCT (PADIMAC)

Rakesh Popat, MD PhD, Ruth Mary De Tute, BSc,MSc, Nicholas Counsell, Dunnya De-Silva, Beth Phillips, MBBS, FRCPath, BSc, James D Cavenagh, Toyin Adedayo, Nivette Braganza, Claire Roddie, PhD MD, Mathew Streetly, Stephen Schey, MBBS, Mickey Koh, MD PhD, Josephine Crowe, Michael F. Quinn, FRCPath, MB, MD MRCP, Shirley D'Sa, MD FRCP, FRCPath, Andres E. Virchis, FRCP, FRCPath, Gordon Cook, PhD, Charles R Crawley, Guy Pratt, MD FRCP, FRCPath, Mark Cook, MBChB,PhD, Paul Smith, Laura Clifton-Hadley, PhDBSc, Neil Rabin, Roger G Owen, MD, Kwee Yong, PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 1864.
https://doi.org/10.1182/blood.V130.Suppl_1.1864.1864
Published: 2017
Journal Articles

Novel In Vitro Experimental Platform for High Throughput Analysis of the Effect of Drugs on Multiple Myeloma Cells and the Tumour Microenvironment In a Co-Culture Setting

Karthik Ramasamy, MBBS, MRCP, FRCPath, Hazera Khatun, Lee Macpherson, Stephen Schey, MBBS, Yolanda Calle
Journal: Blood
Blood (2010) 116 (21): 982.
https://doi.org/10.1182/blood.V116.21.982.982
Published: 2010
Journal Articles

Direct Effect on the Stroma by the Conventional Anti-Multiple Myeloma Drug Dexamethasone Results In Resistance of Multiple Myeloma Plasma Cells Against Therapy. Sensitisation to Dexamethasone by the Kinase Inhibitor Dasatinib

Karthik Ramasamy, MBBS, MRCP, FRCPath, Hazera Khatun, Lee Macpherson, Ghulam J. Mufti, DM, FRCP, FRCPath, Stephen Schey, MBBS, Yolanda Calle
Journal: Blood
Blood (2010) 116 (21): 1931.
https://doi.org/10.1182/blood.V116.21.1931.1931
Published: 2010